Central Serous Chorioretinopathy (CSC)NCT07347119
Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Patients
An observational study of Central Serous Chorioretinopathy (CSC), run by Sun Yat-sen University at 1 site in China.
Trial summary
By leveraging parameters including fractal dimension and topological index, we constructed a quantitative evaluation framework for ultra-widefield optical coherence tomography angiography (UWF-OCTA) images in patients with central serous chorioretinopathy (CSC), thus overcoming the limitations of conventional… Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Central Serous Chorioretinopathy (CSC)
- How many people
- 120 participants
- Where
- 1 siteChina
- Study dates
- 18 Dec 2025to 30 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: The study subjects were recruited from outpatients of the Medical Retina Department at Zhongshan Ophthalmic Center, and eligible cases meeting the study criteria were selected from the outpatient medical record system.
Who may be able to join
- Adults aged 18 to 60 years, inclusive;
- Clinical diagnosis of central serous chorioretinopathy (CSC);
- Completion of fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) examinations;
- Completion of ultra-widefield optical coherence tomography angiography (UWF-OCTA) imaging;
- No prior history of pharmacological or surgical treatment for CSC;
- Ability and willingness to provide written informed consent.
Who cannot join
- -Presence of other ophthalmic diseases that may affect retinal or choroidal imaging or analysis, including but not limited to: Significant refractive media opacities interfering with OCTA imaging (e.g., severe cataract, vitreous hemorrhage);
- Presence of systemic diseases that may affect study outcomes or participant safety;
- Pregnant or lactating women;
- History of psychiatric or mental disorders that may impair compliance;
- Hemorrhagic diathesis or requirement for long-term anticoagulant therapy;
- History of long-term systemic medication use that may affect choroidal or retinal circulation;
Show all 12Show fewer
- Presence of severe and/or uncontrolled comorbid medical conditions, including but not limited to:
- Uncontrolled diabetes mellitus; Uncontrolled hypertension; Active uncontrolled infection; Chronic obstructive pulmonary disease (COPD) with dyspnea at rest;
- History of intraocular surgery or intravitreal injection within the past 6 months;
- High refractive error defined as:
- Spherical equivalent (SE) < -6.0 diopters or > +3.0 diopters, or Axial length (AL) > 26.0 mm;
- -Any other condition that, in the opinion of the investigator, would make participation unsafe or interfere with protocol adherence.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, Guangdong, 510060
Rongtian Chen, 16619724130, 376126340@qq.com
Chenjin Jin, PH.D
About this study
By leveraging parameters including fractal dimension and topological index, we constructed a quantitative evaluation framework for ultra-widefield optical coherence tomography angiography (UWF-OCTA) images in patients with central serous chorioretinopathy (CSC), thus overcoming the limitations of conventional qualitative analysis.
Read the detailed description
Central serous chorioretinopathy (CSC) is a macular disorder characterized by choroidal hyperpermeability and serous retinal detachment, with chronicity leading to irreversible visual impairment. Optical coherence tomography angiography (OCTA) allows non-invasive, high-resolution 3D imaging of choroidal microcirculation, but traditional OCTA analysis relies on qualitative assessment, which cannot quantify vascular structural heterogeneity.
This prospective cohort study will enroll 120 subjects, including CSC patients and healthy controls, who will be allocated to acute, chronic, recurrent CSC groups, or healthy control group. Ultra-widefield swept-source OCTA (UWF SS-OCTA) will be used to capture choroidal vascular images. Geometric parameters (fractal dimension, topological index, 3D vascular diameter) will quantify vascular complexity, distribution, and morphology. Strict inclusion/exclusion criteria and matching for age, gender, and refraction will ensure baseline comparability. Follow-up visits will be conducted at 1, 3, 6, and 12 months post-treatment, with repeated OCTA to evaluate dynamic changes in geometric parameters and their associations with treatment response.
This study innovatively integrates geometric methods with UWF-OCTA to establish a quantitative choroidal vascular evaluation framework for CSC. It aims to identify stage-specific vascular characteristics, explore correlations between geometric markers (e.g., dynamic fractal dimension changes) and the efficacy of laser photocoagulation/anti-VEGF therapy, and validate these markers as non-invasive prognostic indicators. UWF-OCTA will enable comprehensive detection of vascular abnormalities, providing evidence for precise CSC management.
- Conditions
- Central Serous Chorioretinopathy (CSC)
- Keywords
- Central Serous Chorioretinopathy, Ultra-Widefield Optical Coherence Tomography Angiography, Geometry
- Medical subject headings
- Central Serous Chorioretinopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Acute Central Serous Chorioretinopathy | Clinically, serous retinal detachment (SRD) can be detected via fundus examination and optical coherence tomography (OCT), along with focal or multifocal retinal pigment epithelium (RPE) changes confined to small pigment epithelial detachment (PED) lesions. Fundus fluorescein angiography (FFA) demonstrates RPE leakage. SRD typically resolves within 3-4 months, and in most cases, no long-term symptoms persist except for color discrimination deficits in some patients. | |
| Chronic Central Serous Chorioretinopathy | When the disease course exceeds 4-6 months, obvious multifocal atrophic retinal pigment epithelium (RPE) changes, multifocal leakage, and extensive RPE atrophy can be observed. Fundus autofluorescence (FAF) shows hypofluorescence in the RPE-damaged areas. | |
| Recurrent Central Serous Chorioretinopathy | The patient has a history of one or more previous episodes, during which the symptoms completely resolved or significantly improved, and optical coherence tomography (OCT) examination showed complete absorption of subretinal fluid, with reattachment of the neurosensory retina. After complete remission of the first (or previous) episode (an interval of at least 3-6 months is generally considered), the patient develops typical symptoms of central serous chorioretinopathy (CSC) again, accompanied by objective evidence of the acute or chronic phase, such as changes detected by OCT or fundus fluorescein angiography (FFA). | |
| Control Group | Healthy control subjects without any local or systemic diseases |
What is being measured
The primary outcome is the main question the study is designed to answer.
Choroidal Vascular Fractal Dimension
Choroidal vascular fractal dimension quantified from optical coherence tomography angiography (OCTA) images.
Measured: Baseline, 1 month, 3 months, 6 months, and 12 months
Secondary outcomes (7)
Maximum subretinal fluid height
The maximum height of subretinal fluid measured in micrometers (μm) on optical coherence tomography angiography (OCTA) images.
Measured: Baseline, 1 month, 3 months, 6 months, and 12 months
Subretinal fluid area
The basal area of subretinal fluid measured in square millimeters (mm²) on optical coherence tomography angiography (OCTA) images.
Measured: Baseline, 1 month, 3 months, 6 months, and 12 months
Subretinal fluid volume
The volume of subretinal fluid measured in cubic millimeters (mm³) on optical coherence tomography angiography (OCTA) images.
Measured: Baseline, 1 month, 3 months, 6 months, and 12 months
Choroidal vascular branching index
The branching index of choroidal blood vessels quantified from optical coherence tomography angiography (OCTA) images.
Measured: Baseline, 1 month, 3 months, 6 months, and 12 months
Choroidal Vascular Connectivity Index
The connectivity index of choroidal blood vessels quantified from optical coherence tomography angiography (OCTA) images.
Measured: Baseline, 1 month, 3 months, 6 months, and 12 months
Mean curvature of choroidal blood vessels
The mean curvature of choroidal blood vessels quantified from optical coherence tomography angiography (OCTA) images.
Measured: Baseline, 1 month, 3 months, 6 months, and 12 months
Mean curvature of retinal blood vessels
The mean curvature of retinal blood vessels quantified from optical coherence tomography angiography (OCTA) images.
Measured: Baseline, 1 month, 3 months, 6 months, and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2026
- Study start18 Dec 2025 (estimated)
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Central Serous Chorioretinopathy (CSC)Studies of the same condition, open and under way.
- More trials run by Sun Yat-sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sun Yat-sen University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jin Chen-jin, Sun Yat-sen University
- Investigators
- Chenjin Jin, PH.D, Principal investigator, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong 510060
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07347119
- Sponsor's protocol ID
- 2025KYPJ135
- Status last verified
- Jan 2026
- First submitted
- 17 Dec 2025
- Last updated
- 16 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Patients
- ClinicalTrials.gov ID
- NCT07347119
- Acronym / sponsor ID
- 2025KYPJ135
- Conditions
- Central Serous Chorioretinopathy (CSC)
- Keywords
- Central Serous Chorioretinopathy, Ultra-Widefield Optical Coherence Tomography Angiography, Geometry
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Sun Yat-sen UniversityUniversity, hospital or other
- Study start
- 18 Dec 2025 (estimated)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 16 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
By leveraging parameters including fractal dimension and topological index, we constructed a quantitative evaluation framework for ultra-widefield optical coherence tomography angiography (UWF-OCTA) images in patients with central serous chorioretinopathy (CSC), thus overcoming the limitations of conventional qualitative analysis.
Detailed description
Central serous chorioretinopathy (CSC) is a macular disorder characterized by choroidal hyperpermeability and serous retinal detachment, with chronicity leading to irreversible visual impairment. Optical coherence tomography angiography (OCTA) allows non-invasive, high-resolution 3D imaging of choroidal microcirculation, but traditional OCTA analysis relies on qualitative assessment, which cannot quantify vascular structural heterogeneity.
This prospective cohort study will enroll 120 subjects, including CSC patients and healthy controls, who will be allocated to acute, chronic, recurrent CSC groups, or healthy control group. Ultra-widefield swept-source OCTA (UWF SS-OCTA) will be used to capture choroidal vascular images. Geometric parameters (fractal dimension, topological index, 3D vascular diameter) will quantify vascular complexity, distribution, and morphology. Strict inclusion/exclusion criteria and matching for age, gender, and refraction will ensure baseline comparability. Follow-up visits will be conducted at 1, 3, 6, and 12 months post-treatment, with repeated OCTA to evaluate dynamic changes in geometric parameters and their associations with treatment response.
This study innovatively integrates geometric methods with UWF-OCTA to establish a quantitative choroidal vascular evaluation framework for CSC. It aims to identify stage-specific vascular characteristics, explore correlations between geometric markers (e.g., dynamic fractal dimension changes) and the efficacy of laser photocoagulation/anti-VEGF therapy, and validate these markers as non-invasive prognostic indicators. UWF-OCTA will enable comprehensive detection of vascular abnormalities, providing evidence for precise CSC management.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Acute Central Serous Chorioretinopathy | – | –Clinically, serous retinal detachment (SRD) can be detected via fundus examination and optical coherence tomography (OCT), along with focal or multifocal retinal pigment epithelium (RPE) changes confined to small pigment epithelial detachment (PED) lesions. Fundus fluorescein angiography (FFA) demonstrates RPE leakage. SRD typically resolves within 3-4 months, and in most cases, no long-term symptoms persist except for color discrimination deficits in some patients. |
| Chronic Central Serous Chorioretinopathy | – | –When the disease course exceeds 4-6 months, obvious multifocal atrophic retinal pigment epithelium (RPE) changes, multifocal leakage, and extensive RPE atrophy can be observed. Fundus autofluorescence (FAF) shows hypofluorescence in the RPE-damaged areas. |
| Recurrent Central Serous Chorioretinopathy | – | –The patient has a history of one or more previous episodes, during which the symptoms completely resolved or significantly improved, and optical coherence tomography (OCT) examination showed complete absorption of subretinal fluid, with reattachment of the neurosensory retina. After complete remission of the first (or previous) episode (an interval of at least 3-6 months is generally considered), the patient develops typical symptoms of central serous chorioretinopathy (CSC) again, accompanied by objective evidence of the acute or chronic phase, such as changes detected by OCT or fundus fluorescein angiography (FFA). |
| Control Group | – | –Healthy control subjects without any local or systemic diseases |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- The study subjects were recruited from outpatients of the Medical Retina Department at Zhongshan Ophthalmic Center, and eligible cases meeting the study criteria were selected from the outpatient medical record system.
Key inclusion criteria (6 listed)
- Adults aged 18 to 60 years, inclusive;
- Clinical diagnosis of central serous chorioretinopathy (CSC);
- Completion of fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) examinations;
- Completion of ultra-widefield optical coherence tomography angiography (UWF-OCTA) imaging;
- No prior history of pharmacological or surgical treatment for CSC;
Key exclusion criteria (12 listed)
- -Presence of other ophthalmic diseases that may affect retinal or choroidal imaging or analysis, including but not limited to: Significant refractive media opacities interfering with OCTA imaging (e.g., severe cataract, vitreous hemorrhage);
- Presence of systemic diseases that may affect study outcomes or participant safety;
- Pregnant or lactating women;
- History of psychiatric or mental disorders that may impair compliance;
- Hemorrhagic diathesis or requirement for long-term anticoagulant therapy;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Choroidal Vascular Fractal Dimension
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Choroidal vascular fractal dimension quantified from optical coherence tomography angiography (OCTA) images.
7 secondary outcomes
Maximum subretinal fluid height
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Subretinal fluid area
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Subretinal fluid volume
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Choroidal vascular branching index
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Choroidal Vascular Connectivity Index
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Mean curvature of choroidal blood vessels
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Mean curvature of retinal blood vessels
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Central Serous Chorioretinopathy (CSC)
Not yet recruitingPhase 2
Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial
Central Serous Chorioretinopathy (CSC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chenjin Jin, PH.D principal investigator
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong 510060
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Central Serous Chorioretinopathy (CSC), run by Sun Yat-sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rongtian Chen (16619724130, 376126340@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Choroidal Vascular Fractal Dimension (time frame: Baseline, 1 month, 3 months, 6 months, and 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2026.